SS Innovations International (SSII) AI Stock Analysis

• Market Cap: $1.85B
• Dividend Yield: N/A
• Average Volume (3M): 121.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 9.11
• Revenue Growth: 135.60%
• EPS Growth: 66.47%
• Country: US
• Employees: 378
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 193,588,410
• 10 Day Avg. Volume: 239,396
• 30 Day Avg. Volume: 121,157
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.61
• Enterprise Value/Revenue: 61.10
• Enterprise Value/Gross Profit: 183.86
• Enterprise Value/Ebitda: -58.22
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: $9.50 ▼(-4.81% Downside)

SS Innovations International's stock score is primarily influenced by its financial performance challenges, particularly in profitability and cash flow management. Despite strong revenue growth, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation score. Technical analysis shows bullish momentum, but potential overbought conditions could pose risks.

SS Innovations International Business Overview & Revenue Model

Company Description

SS Innovations International (SSII) is a global leader in technology solutions, specializing in the development and implementation of advanced software, hardware, and integrated systems across various sectors, including healthcare, finance, and manufacturing. With a commitment to innovation, SSII offers a range of products and services, such as cloud computing solutions, data analytics, and Internet of Things (IoT) devices, aimed at enhancing operational efficiency and driving digital transformation for its clients.

How the Company Makes Money

SS Innovations International generates revenue through multiple streams, primarily by offering software licensing and subscription-based services for its proprietary technology solutions. The company also earns income from consulting services, where it assists clients in customizing and implementing its products to meet specific business needs. Additionally, SSII engages in strategic partnerships with other technology firms and industry leaders, allowing it to expand its reach and enhance its offerings. Revenue is further supplemented by hardware sales, particularly in the IoT segment, where the company provides devices that integrate with its software solutions. Furthermore, SSII may benefit from maintenance contracts and ongoing support services, ensuring a steady income from existing clients.

SS Innovations International Financial Statement Overview

Summary

SS Innovations International shows strong revenue growth but faces significant challenges in profitability and cash flow generation. The balance sheet is improving, with a manageable debt-to-equity ratio and positive equity, but high liabilities remain a concern.

Income Statement

The income statement shows a significant challenge in profitability with negative net income and EBIT margins in the TTM period. Revenue growth is strong, particularly from 2021 to 2023, but the inability to convert this into profitability is concerning. The gross profit margin is positive but overshadowed by high operating costs leading to negative EBITDA and net profit margins.

Balance Sheet

The balance sheet reflects a moderate financial position with an improving equity situation. The debt-to-equity ratio is manageable, and equity has turned positive compared to previous years, indicating stabilization. However, the company still shows a significant amount of total liabilities which may present a risk if not managed properly.

Cash Flow

Cash flow analysis indicates challenges in generating positive operating and free cash flow. There is a consistent negative free cash flow, which may hinder financial flexibility. The operating cash flow to net income ratio suggests inefficiencies in converting revenue to cash. Positive financing activities show reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.54M	20.65M	5.88M	1.46M	0.00	0.00
Gross Profit	6.16M	8.45M	713.45K	489.59K	-18.79K	-37.43K
EBITDA	-19.45M	-17.74M	-20.26M	-5.31M	-1.47M	-1.09M
Net Income	-22.18M	-19.15M	-20.94M	-5.60M	-1.48M	-1.12M
Balance Sheet
Total Assets	63.46M	42.39M	25.48M	8.68M	428.61K	317.87K
Cash, Cash Equivalents and Short-Term Investments	15.87M	466.50K	7.03M	1.57M	405.77K	160.71K
Total Debt	10.45M	18.20M	8.22M	10.24M	145.00K	195.00K
Total Liabilities	22.90M	28.93M	11.18M	11.14M	287.28K	1.19M
Stockholders Equity	40.55M	13.46M	14.30M	-2.46M	141.33K	-869.05K
Cash Flow
Free Cash Flow	-17.16M	-10.16M	-16.34M	-5.78M	-363.03K	-94.54K
Operating Cash Flow	-16.94M	-9.50M	-13.57M	-5.56M	-363.03K	-90.54K
Investing Cash Flow	2.67M	-661.48K	-2.30M	-2.74M	38.15K	-44.00K
Financing Cash Flow	29.09M	9.43M	16.73M	9.29M	569.95K	266.77K

SS Innovations International Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SSII, the sentiment is Positive. The current price of 9.98 is above the 20-day moving average (MA) of 7.75, above the 50-day MA of 6.96, and above the 200-day MA of 7.80, indicating a bullish trend. The MACD of 0.88 indicates Negative momentum. The RSI at 63.31 is Neutral, neither overbought nor oversold. The STOCH value of 88.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SSII.

SS Innovations International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CNMD	74 Outperform	$1.51B	13.63	11.69%	1.66%	4.02%	11.32%
AORT	53 Neutral	$2.05B	-100.98	-5.01%	―	7.44%	-109.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IART	51 Neutral	$1.20B	―	-38.92%	―	3.53%	-2309.98%
ESTA	49 Neutral	$1.44B	-16.21	-261.18%	―	17.22%	1.65%
TNDM	48 Neutral	$1.01B	―	-111.91%	―	25.84%	-47.67%
SSII	48 Neutral	$1.85B	―	-39.11%	―	135.60%	66.47%

SS Innovations International Corporate Events

SS Innovations to Attend Upcoming Investor Conferences

On October 21, 2025, SS Innovations International announced that its executives, Dr. Sudhir Srivastava and Dr. Vishwa Srivastava, will participate in upcoming investor conferences, including the UBS Global Healthcare Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025. These events will provide opportunities for one-on-one and small group meetings, and a live webcast of the Stifel presentation will be available on the company’s website. This participation underscores the company’s commitment to engaging with investors and stakeholders, potentially enhancing its industry positioning and visibility.

The most recent analyst rating on (SSII) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations Unveils Growth Plans in October 2025

SS Innovations International has released an updated company presentation for October 2025, highlighting its growth and strategic plans. The company has seen significant expansion, with 125 SSi Mantra systems installed and over 6,000 surgeries performed across nine specialties. The presentation underscores the company’s commitment to global expansion, particularly into Europe and the United States, and its strategy for long-term sustainable growth. The leadership team, with a proven track record in surgical robotics, aims to leverage favorable industry trends and a growing market to enhance its positioning and deliver advanced surgical solutions.

The most recent analyst rating on (SSII) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations Completes Key Study for FDA Submission

SS Innovations International announced the successful completion of a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025. This milestone is crucial for their anticipated 510(k) premarket notification submission to the FDA in the fourth quarter of 2025, which could potentially allow the SSi Mantra to be marketed in the U.S. by the first half of 2026. The company has installed 125 SSi Mantra systems across six countries, with over 6,000 surgical procedures performed, highlighting its growing global footprint.

The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations Appoints Naveen Kumar Amar as CFO

On September 26, 2025, SS Innovations International announced the appointment of Naveen Kumar Amar as Chief Financial Officer, effective September 24, 2025. Mr. Amar, with over 27 years of global finance experience, brings a strong track record in building finance operations and successful businesses across diverse industries. His appointment is expected to support SS Innovations’ expansion of its advanced, cost-efficient SSi Mantra surgical robotic system and drive growth, enhancing shareholder value.

The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations Completes First Pediatric Telesurgery

On September 16, 2025, SS Innovations International announced the successful completion of the world’s first pediatric pyeloplasty telesurgery using its SSi Mantra surgical robotic system. This milestone, performed remotely by Dr. Chandra Mohan Vaddi from nearly 1,000 miles away, underscores the system’s potential to enhance precision and accessibility in pediatric surgery. The achievement highlights the company’s commitment to democratizing advanced surgical care, particularly in underserved regions, and positions SS Innovations as a leader in the growing field of robotic telesurgery.

The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations Achieves Milestone with First Robotic Telesurgery

On September 9, 2025, SS Innovations International announced the successful completion of the first robotic telesurgery performed from its MantraM mobile robotic telesurgery unit. This milestone, achieved by Dr. Priya Bhave Chittawar, involved a complex hysterectomy conducted remotely in Bhopal, India, highlighting the company’s mission to provide advanced surgical care to underserved populations. The MantraM bus tour, launched in July 2025 across India, aims to demonstrate the capabilities of SS Innovations’ mobile unit and SSi Mantra system, focusing on hospitals and medical institutions in underserved communities.

The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations Reports Record Q2 2025 Revenue Growth

On August 7, 2025, SS Innovations International reported a significant increase in revenue and gross profit for the second quarter of 2025, driven by higher sales of the SSi Mantra 3 robotic system. The company achieved record quarterly revenue of $10 million, a 121.8% increase from the previous year, and gross profit more than tripled due to expanded gross margins. The company also highlighted several pioneering achievements in robotic surgery, including the world’s first robotic telesurgery for weight loss and intercontinental robotic cardiac telesurgery. SS Innovations’ uplisting to Nasdaq and upcoming regulatory submissions are expected to support its global expansion and continued growth.

SS Innovations CFO Arvind Palaniappan Steps Down

On July 23, 2025, Arvind Palaniappan stepped down as the Interim Chief Financial Officer of SS Innovations International. The company is currently searching for a permanent successor, with Dr. Vishwajyoti P. Srivastava, CEO of Asia Pacific, temporarily taking on the CFO responsibilities, indicating a strategic transition phase for the company.